Relenza, the new flu treatment controversially excluded from the NHS because
a panel decided it was not cost-effective, can cause breathing difficulties in
patients with asthma. Glaxo Wellcome, which makes the drug, warned doctors of
the danger last week. The company says the number of people who have suffered
breathing difficulties after taking the drug is tiny, and that the warning is
simply a precaution. But the news is unfortunate, given that flu patients with
chronic lung disease are among the ones most likely to benefit from effective
influenza treatments.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Popular articles
Trending New Scientist articles
1
Where, when and how to watch the 2026 solar eclipse
2
Woman with Alzheimer's starts conversing again after taking psilocybin
3
Faecal transplant makes the brains of old mice act young again
4
How menopause radically changes the brain 鈥 and what happens after
5
If you aren't terrified by this heatwave, you should be
6
Phages could enable us to hijack vaccine immunity to kill cancer cells
7
Most portable air conditioners suck 鈥 but there's an easy fix
8
Our verdict on The Selfish Gene: An unpopular piece of popular science
9
The race to understand how and when Thwaites glacier will collapse
10
I have a 100 per cent chance of getting cancer due to a rare gene
